0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Interleukin 2 trial will try to spark flagging immunity of AIDS patients

Charles Marwick
JAMA. 1983;250(9):1125. doi:10.1001/jama.1983.03340090003001.
Text Size: A A A
Published online

ABSTRACT

The National Institutes of Health is initiating a phase I clinical trial of the lymphokine interleukin 2 (IL-2) that it hopes may revive the immunologic systems of patients with acquired immune deficiency syndrome (AIDS).

Behind this approach lie some basic research findings by a number of groups into the immunologic characteristics of the disease. For example, Gerald V. Quinnan, MD, chief of the Division of Virology in the office of biologics of the Food and Drug Administration, and his associates, including Alain H. Rook, MD, have found that cytotoxic T lymphocytes from patients with AIDS have a marked depression in their ability to respond to viral infection. (Cytotoxic T lymphocytes are cells especially primed to kill only cells specifically infected by a "priming" agent.) In addition, the investigators have found that natural killer (NK) cells from patients with AIDS are depressed in activity compared with NK cells from normal persons.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

* * SCHEDULED MAINTENANCE * *

Our websites may be periodically unavailable between midnight and 04:00 ET Thursday, July 10th, for regularly scheduled maintenance.

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();